Dalcetrapib vs Placebo: Composite Endpoint of Cardiovascular Death, Resuscitated Cardiac Arrest, Non-Fatal Myocardial Infarction, Non-Fatal Stroke, Hospitalization for ACS (With Electrocardiogram Abnormalities) or Unanticipated Coronary Revascularization
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.153 | 0.141 | 0.167 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.153 | 0.141 | 0.166 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | 0.000249 | -0.0178 | 0.0183 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 1 | 0.891 | 1.13 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 1 | 0.872 | 1.15 | log | ClinicalTrials.gov | |
| Number needed to treat, for one more participant with the outcome on Dalcetrapib than on Placebo | 4,010 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Dalcetrapib | Participants received dalcetrapib 600 mg (two 300 mg tablets) orally once daily.~dalcetrapib: Cholesterol Ester Transfer Protein inhibitor, 300 mg tablets | 471 | 3,071 | OG001 | ClinicalTrials.gov |
| Group 2 | Placebo | Participants received dalcetrapib placebo tablets matching dalcetrapib orally once daily.~Placebo: dalcetrapib matching placebo tablets | 471 | 3,076 | OG000 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | SECONDARY | ClinicalTrials.gov |
| Title | Composite Endpoint of Cardiovascular Death, Resuscitated Cardiac Arrest, Non-Fatal Myocardial Infarction, Non-Fatal Stroke, Hospitalization for ACS (With Electrocardiogram Abnormalities) or Unanticipated Coronary Revascularization | ClinicalTrials.gov |
| Description | All efficacy endpoints were adjudicated by an independent clinical endpoint committee (CEC). The primary efficacy endpoint was the time from randomization to the first occurrence of any component of the composite endpoint, which included death from cardiovascular causes, resuscitated cardiac arrest, non-fatal myocardial infarction, non-fatal stroke, hospitalization for acute coronary syndrome (with electrocardiogram abnormalities) or unanticipated coronary revascularization, as positively adjudicated by the CEC. | ClinicalTrials.gov |
| Time frame | From randomization to the first occurrence of any component of the composite secondary endpoint (median duration of follow-up was 39.9 months) | ClinicalTrials.gov |
| Population | All subjects randomized to treatment | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS | ClinicalTrials.gov |
| NCT number | NCT02525939 | ClinicalTrials.gov |
| Phases | PHASE3 | ClinicalTrials.gov |
| Conditions | Acute Coronary Syndrome | ClinicalTrials.gov |
| Interventions | dalcetrapib, Placebo | ClinicalTrials.gov |
| Lead sponsor | DalCor Pharmaceuticals | ClinicalTrials.gov |
| Results first posted | 2022-10-12 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT02525939?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.